BioWorld Asia

April 24, 2002

Xenova Enters Potential $63M Deal With Genentech For OX40

LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International) Read More

Finnish Companies Biotie, Contral, Carbion Plan Three-Way Merger

Leukemia Case Report Gives Gene Therapy Projects Pause For Thought

Apovia Raises EUR19M Privately To Fund Vaccine Development

YM BioSciences Plans Floats On AIM, TSE To Raise Up To C$40M

Faust Pharmaceuticals Obtains $2.6M To Develop CNS Drugs

Report Says EU Biotech Trails U.S. Due To Lack Of Coordination

Molecular Skincare Spun Out To Develop Skin Disease Treatments

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...